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1. Introduction 
Life is getting complicated in the world of local thyroid hormones (THs) regulation. On 
account of TH action can be controlled in individual cells through selective TH uptake and 
intracellular TH metabolism, the placenta is an important link in the maternal-fetal 
communication network for THs which are essential for the normal development and 
differentiation of the fetus [1-3]. Generally, intracellular activation or inactivation of L-
thyroxine (T4) and 3,5,3'-triiodothyronine (T3) in turn is determined by three types of 
iodothyronine deiodinases (Ds), namely DI, DII, and DIII [4-7]. The placenta transports and 
metabolizes maternal THs, and mainly expresses DIII, which inactivates T4 and other 
iodothyronines and thus limits the transfer of maternal active THs to the fetus in the late 
pregnancy [8]. DII is also active in the placenta and locally provides active T3 from the 
maternal prohormone T4 for placental metabolic functions [1,2]. The placental expression of 
DI, which also activates T4 to T3, is still controversial. Because of the lipophilic nature of 
THs, it was thought that they traversed the plasma membrane by simple diffusion [9,10]. 
The transport of T4 and T3 in and out of cells is controlled by several classes of 
transmembrane TH-transporters (THTs) [11], including members of the organic anion 
transporter family (OATP), L-type amino acid transporters (LATs), Na+/Taurocholate 
cotransporting polypeptide (NTCP), and monocarboxylate transporters (MCTs) [10,12]. 
Particularly, monocarboxylate transporter 8 (MCT8) has recently been identified as an active 
and specific TH transporter. Also, placental membranes are also involved in 4'-OH-sulfation 
reactions of iodothyronines [8]. Sulfation (S) plays a role in TH metabolism by interacting 
between the deiodination and sulfation pathways of TH [13]. Interestingly, placental cells 
express high affinity, stereo-specific, energy-dependent uptake systems for T4 and T3. On 
the other hand, the cellular activity of THs is usually classified as genomic (nuclear) and 
non-genomic (initiated either at cytoplasm or at membrane TH receptors) [14-21]. Binding of 
T3 to its nuclear thyroid receptors (TRs) directly affects transcription of many genes that are 
important in development [22].  
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In general, pregnancy is accompanied by profound alterations in the thyroidal economy 
(hypo- or hyper-thyroidism), resulting from a complex combination of factors specific to the 
pregnant state, which together concur to stimulate the maternal thyroid machinery [1,23]. 
Also, clinical studies showed that maternal TH deficiency during the first trimester of 
pregnancy can affect the outcome of human neurodevelopment [24,25]. Experiments in rats 
showed that early maternal TH deficiency affects neuronal migration in the cortex [26], 
while maternal hyperthyroidism too can disturb fetal brain development [27]. Experimental 
data on the mechanisms regulating intracellular TH availability and action prior to the onset 
of fetal TH secretion, however, remain scarce. Thus, in this chapter will be aware about the 
significant roles of THs, their metabolism by Ds and sulfotransferases, their transport by 
THTs and their binding to TRs from the mother via the placenta to the fetal compartment 
especially during the gestation period in both human and animals. 
2. Placental transport of thyroid hormones 
2.1. By thyroid hormone-deiodinases (Table 1 and Figure 1) 
The synthesis of THs is regulated through the hypothalamus–pituitary–thyroid (HPT) axis 
[28] and the follicular cells of the thyroid gland synthesize and secrete T4 and T3 [1,2,21]. 
This process is under the control of the circulating TH levels through negative feedback 
loops of this axis [28]. The availability of the active ligand T3 within tissues is locally 
determined by the action of the iodothyronine deiodinases (Ds) [29]. There are three 
selenocysteine monodeiodinase subtypes (DI, DII and DIII) [30]. Whilst T3 is generated by 
the activity of DI and DII, via 5'- reductive or outer ring deiodination (ORD) of the T4 [31], 
DIII activity (and to a lesser extent that of DI) convert T4 to 3,3',5'-tri-iodothyronine (reverse 
T3; rT3) and T3 into 3,3'-T2 via inner ring deiodination (IRD), in effect acting as a 
deactivating enzyme for THs [13,32].  
Activities of all three iodothyronine deiodinase subtypes have been demonstrated in most 
rat placenta [33]. However, in contrast to man, rodent total serum T3 and T4 increase with 
gestation [34] and the predominant subtype expressed appears to be DIII [35], although 
DII is also present with significant activity [36]. Placental DIII activity is much greater 
(approx. 200 times) than DII activity; however, the activity and expression of both DII and 
DIII fall as gestation progresses [37-40]. Placental DII provides T3 for ‘housekeeping’ 
processes, and as indicated above, its activity is much less than that of D3 [40]. DII has 
been localized to the villous cytotrophoblasts in the first trimester and 
syncytiotrophoblasts in the third trimester, whereas DIII has been localized to the villous 
syncytiotrophoblasts in both the first and third trimesters of pregnancy [39]. Both DIII 
mRNA and activity are present at the implantation site in rodents, as early as gestational 
day 9 (GD 9), being expressed in mesometrial and antimesometrial decidual tissue [41]. 
Also, in rabbit [42] and pig [43], the placenta appears to express DIII activity 
predominantly. The positioning of the deiodinases, particularly DIII, suggests that they 
might regulate the amount of maternal TH reaching fetal circulation [40]. Interestingly, 
 
Maternal-Fetal Thyroid Interactions 127 
however, fetuses with total thyroid agenesis but with evidence of circulating maternal TH 
have normal placental DIII activity, suggesting that there might be other factors 
modulating T4 access to the deiodinases, such as intracellular protection of TH by TH-
binding protein (THBP) [40,44]. Collectively, express placental Ds (II, III) may play a 
critical role in delivery of TH to the fetus as summarized in figure1 [2,45-47] and table 1 
[1,2,31,48].  
 
Figure 1. Summary about the interactions of maternal, placental and fetal thyroid metabolism. I, II 
and III denote deiodinases type 1 (DI), type two (DII) and type three (DIII). SO4 is a sulfation 
pathway and –SO4 is a desulfation pathway. CNS is central nervous system, TRH is thyroid releasing 
hormone, M-TRH is maternal thyroid releasing hormone, TSH is thyrotrophin, T2 is 
diiodothyronine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T4 is thyroxine, T2S is 
diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse 
triiodothyronine sulfate, MCT8 is monocarboxylate transporter 8, OATP4A1 is organic anion 
transporter 4A1, TBG is thyroxin binding globulin, TTR is transthyretin, ACTH is 
adrenocorticotrophin and hCG is human chorionic gonadotrophin. 
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Characteristic DI DII DIII 
Reaction kinetics Ping-pong Sequential
Reaction catalyzed
(Deiodination) 
5 or 5' (ORD+IRD) 5' (ORD) 5 (IRD) 
Main form T4-T3, rT3- T2 - T4- rT3, T3- T2 - T4- rT3- T2 
Substrate preference 5: T4S>T3S>>T3, T4
5': rT3, rT3S>T2S>>T4 
T4>rT3 T3>T4
Sulfation of substrates Stimulation Inhibition
Substrate limiting KM 0.5 mM 1–2 nM 5–20 mM 
In vitro cofactor limiting
KM 
1–10 Mm DTT >10 mM DTT =70 mM DTT 
 
Molecular mass (kDa) 29 30 32
Selenocysteine present
Homodimer Yes
Location - Liver, kidney,
thyroid and pituitary.
- Pituitary, brain,
BAT, thyroida, 
hearta and skeletal 
musclea. 
- Brain, skin, uterus, 
placenta, fetus and 
in other sites of the 
maternal- fetal 
interface, such as 
the umbilical 
arteries and veins. 
Subcellular location - Liver: endoplasmic 
reticulum. - kidney: 
basolateral plasma 
membrane 
- Microsomal membranes
Functions - Production serum
T3 and the clearance 
of serum rT3. 
- Catalyzes the
outer ring 
deiodination of T4 
to T3 and is thus  
important for the 
local production  
of T3. 
- Catalyzes the 
inner ring 
deiodination of T4 
to rT3 and of T3 to 
3,3'-T2. 
Activity in 
hypothyroidism 
- Decrease in liver
and kidney. 
- increase in thyroid. 
- Increase in all
tissues. 
- Decrease in brain. 
Activity in 
hyperthyroidism 
- Unknown in liver
and kidney. 
- Increase in thyroid. 
- Decrease in most
tissues. 
- Increase in 
thyroida. 
- Increase in brain. 
Low-T3 syndrome - Decrease - No change
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Active site residues - Selenocysteine
histidine and 
phenylalanine.
- (Seleno-)cysteine? - Selenocysteine 
Human gene structure
and location 
- 1p32-p33, 17.5 kb 
and 4 exons.
- 14q24.3, 2 exons,
and 7.4-kb intron.
- 14q32 
Promoter elements
 
- TRE, RXR, no CAAT
or TATA box.
--
Propylthiouracil
inhibitor 
++++ + +/-
Aurothioglucose
inhibitor 
++
Iopanoic acid inhibitor +++ ++++ +++
Thiouracils ++++
 
-/+ -
iodoacetate + ?
flavonoids + +++
a Humans only. T2 is diiodothyronine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T4 is thyroxine, T2S is 
diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse triiodothyronine 
sulfate, ORD is outer ring deiodination, IRD is inner ring deiodination, TRE is T3-responsive element, RXR is retinoid 
X receptors and DDT is dithiols. 
Table 1. General characteristics of the iodothyronine deiodinases. 
2.2. By thyroid hormone-transporters (THTs) (Tables 2 & 3 and Figure 1) 
Membrane transporters mediate cellular uptake and efflux of TH [12,40,49]. The ability to 
transport TH has been described in members of different transporter groups including the 
monocarboxylate transporters (MCT), L-type amino acid transporters (LAT), Na+/Taurocholate 
cotransporting polypeptide (NTCP), and organic anion transporting polypeptides (OATP) 
[50]. With the exception of MCT8, these transporters do not exclusively transport TH and they 
all have slightly different affinities for specific forms of TH. To date six different THTs are 
known to be present in the placenta: MCT8, MCT10, LAT1, LAT2, OATP1A2 and OATP4A1 
but their relative contributions to placental TH transport are unknown [50-55]. Also, their 
anatomical localization, ontogeny in the human placenta and relative affinity for the TH and 
thyronines are very complex. MCT8, MCT10, OATP1A2, OATP4A1 and LAT1 are expressed 
in villous syncytiotrophoblasts, and MCT8, MCT10 and OATP1A2 in cytotrophoblasts [50]. 
Although transporters in the apical syncytiotrophoblast membrane are well placed to 
maximize maternal cellular TH uptake early in gestation, the large numbers and variety of 
THTs are intriguing [51,53,55]. Moreover, the expression of MCT8 mRNA increased with 
advancing gestation [55] but there is limited information regarding the ontogeny of the other 
THTs. In addition, it is likely that the lower expression of MCT8, MCT10, OATP1A2 and LAT1 
before 14 week compared to term, as well as the nadir in OATP4A1 expression in the late 1st 
and early 2nd trimester, may play a role in the necessary limitation of maternal-fetal TH 
transfer, particularly around the time of onset of endogenous fetal TH production in the early 
2nd trimester [56]. Increased expression of THTs in late gestation is consistent with the proposal 
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that there is continued/ increased maternal to fetal supply of TH in the 3rd trimester despite 
increasing fetal TH production [57]. It is also likely that increased expression of these 
transporters with gestation may also fulfil the increased need for other biological substances 
for fetal growth and development, such as amino acids. The most factors regulating the 
placental expression of these transporters are unknown until now. There are suggestions in 
rodents that the activity of system-L and the expression of MCT8 in non-placental tissues are 
influenced by thyroid status [58] suggesting that TH may be a regulator of its own transporters 
[50]. During the passage of THs from the maternal circulation to the fetal circulation, each THT 
is likely to have a specific role in each different plasma membrane layer, which might include 
cellular influx, efflux, or both [59]. To sum, THTs of the various placental cell types serve as 
channels that help to maintain the differences in the composition of THs and their metabolites 
between maternal and fetal circulations (figure1 [2,45-47] and tables 2 & 3 [51,52,55,59,60,61]). 
The relative contributions of these THTs to the transplacental transport of thyroid hormones 
are still a subject for research.  
Transportera Iodothyronine derivates Specificityb 
MCT8  T3, T4, rT3, T2 +++ 
MCT10  T3, T4 ++ 
OATP1A1  T3, T4, rT3, T2, T4S, T3S, rT3S, T2S + 
OATP1A2  T4, T3, rT3
OATP1A3  T4, T3
OATP1A4 
OATP1A5 
OATP1B1  T4, T3, T3S, T4S, rT3S
OATP1B2  T3, T4
OATP1B3  rT3, T4S, T3S, rT3S
OATP1C1  T4, rT3, T3, T4S ++ 
OATP2B1  T4 + 
OATP3A1 (V1/V2) ++ 
OATP4A1  T3, T4, rT3 + 
OATP4C1  T3, T4
OATP6B1 
OATP6C1 
LAT1  T3, T4, rT3, T2
LAT2 
NTCP  T4, T3, T4S, T3S ++ 
a The human protein symbol is presented, if TH transport has been demonstrated in different species including 
humans. b If a transporter only transports iodothyronine derivatives, specificity is high (+++). If fewer than five other 
ligands are known, specificity is moderate (++). If more than five ligands are known, the transporter is denoted as 
multispecific (+). 
Table 2. Types of thyroid hormone transporters and their iodothyronine derivates. 
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Transporter 
family 
 
Monocarboxylate 
transporters 
 
System L amino 
acidtransporters 
 
Organic anion 
transporting 
polypeptides 
MCT8 MCT10 LAT1 LAT2 OATP1A2 OATP4A1 
Heterodimer N/A 4F2hc N/A 
Additional 
molecules 
transported 
N/A Aromatic 
amino 
acids 
Large neutral 
amino acids 
Amphipathic organic 
compounds 
Localization in 
first and second 
trimestera 
ST, CT, 
EVT 
N/A 
Localization in 
third trimesterb 
ST N/A STap N/A STap 
Km T4 (μM) 4.7c >Km T3d 7.9 8.0 >Km T3 
Km T3 (μM) 4.0c ≤4.0d 0.8 6.5 0.9 
Km rT3 (μM) 2.2c N/A 12.5 N/A 
Km T2 (μM) N/A 7.9 N/A 
aOnly MCT8 has been localized in the placenta in all three trimesters of pregnancy. bLAT1 and OATP4A1 have been 
localized only at term. c These Km values were determined for the rat MCT8 protein expressed in Xenopus laevis 
oocytes. The other Km values shown are mainly from studies using the human gene expressed in X. laevis oocytes. 
dHuman MCT8 or MCT10 transporters expressed in COS1 cells both showed a greater preference for T3 than T4 
uptake. Whereas MCT10 showed a greater capacity than MCT8 to transport T3, MCT8 was found to be a more active 
transporter of T4. 
Abbreviations: CT is cytotrophoblast cells, EVT is extravillous trophoblast cells, N/A is no data available, rT3 is reverse 
T3, ST is syncytiotrophoblast layer and STap is predominantly at apical surface of the ST. 
Table 3. Expression of the thyroid hormone transporters in human placenta. 
2.3. By thyroid hormone-sulfotransferases (Figure 1) 
Sulfation (S) appears to be an important pathway for the reversible inactivation of THs 
during fetal development [2,13,45-47]. Monique Kester and the group from Erasmus 
University have used a rat model to study the regulation of fetal TH status and have also 
extended their studies to human pregnancy [62]. The sulfotransferases catalyze the sulfation 
of the hydroxyl group of compounds, using 3'-phosphoadenosine-5'-phosphsulfate (PAPS) 
as the universal sulfate donor [63]. This co-factor PAPS is synthesized from two ATP 
molecules and inorganic sulfate. Neither the DII or DIII iodothyronines catalyze the 
deiodination of sulfated iodothyronines nor sulfation strongly facilitates the inner ring 
deiodination of T4 and T3 by DI, but blocks the outer ring deiodination of T4 (activation) 
[13,64]. The outer ring deiodination of rT3 by DI is not affected by sulfation [64]. Sulfation 
thus induces the irreversible degradation of TH. Thus, rapid inner ring deiodinations of T4S, 
T3S and out ring deiodination of rT3S lead to high concentrations of these sulfates in plasma 
of adult humans [13,65]. 
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High concentrations of the different iodothyronine sulfates, T4S (thyroxine sulfate), T3S 
(triiodothyronine sulfate), rT3S (reverse triiodothyronine sulfate) and T2S (diiodothyronine 
sulfate), have been documented in human fetal and neonatal plasma as well as in amniotic 
fluid [65,66], and similar findings have been reported for sheep [67]. This has classically 
been explained by the low hepatic DI expression in the human fetus until the postnatal 
period [68] and lack of hepatic DI expression until birth in rats [69]. Also, in the rat placenta, 
where there are insignificant sulfotransferases activities but high DIII activity, irreversible 
inactivation of DIII appears to be the predominant pathway of iodothyronine metabolism 
[13]. In the rat fetal liver, sulfotransferase activity is present from the end of the third 
trimester (GD 17), a time when DI activity is relatively absent [69]. The TH-sulfates may 
accumulate under such circumstances to form a ‘reservoir’ of inactive TH from which active 
hormone may be liberated, in a tissue specific and gestational dependent manner by the 
action of arylsulfases [13]. To date, six members of this family (ARSAeARSF) have been 
identified in humans [13,70]. It is interesting that DIII is abundantly expressed in the human 
placenta [39] and deiodinates T4 and T3 to 3,3'-T2 and rT3, respectively, thus providing 
substrates for these actions. In the human fetal circulation, T4S and in particular T3S, may 
represent a reservoir of inactive TH, from which active hormone may be liberated as 
required (vide supra) [13]. The iodothyronine sulfates in human fetal circulation and 
amniotic fluid may be derived, at least in part, from sulfation of THs by thermostabile 
phenol sulfotransferases in the uterus and placenta [13,45]. This may provide a route for the 
supply of maternal TH to the fetus in addition to placental transfer. Alternatively, 
iodothyronine sulfates may accumulate in the fetal circulation because of the absence of 
hepatic transporters which mediate their removal from plasma. It has been demonstrated 
recently that hepatic uptake of the different iodothyronine sulfates in rats is mediated at 
least in part through the NTCP and OATP families [71]. Thus, the TH-sulfation mechanism 
might be useful for non-invasive prenatal diagnostics of fetal thyroid function which is 
autonomously regulated. The overviews presented here are consistent with the evolving 
view that sulfation is a major chemical defense system in the maternal-fetal thyroid axis and 
will hopefully provide a basis for understanding more about these enzymes. 
2.4. By thyroid hormone-genomic and non-genomic actions (Tables 4 & 5 and 
Figure 2) 
Although the thyroid gland predominantly secretes T4, T3 is the most active TH, since it has 
a higher affinity by the nuclear thyroid hormone receptors (TRs; α, β) (Figure 2A) [75], 
which mediate most actions of these hormones [72,73]. THs are released by the thyroid 
gland to the circulation where they are carried bound to proteins such as thyroxin binding 
globulin (TBG), transthyretin (TTR) or serum albumin (Table 4) [74]. The level of albumin, 
which has the lowest T4 affinity and enables a fast release of T4 [76], gradually decreases 
during pregnancy [77]. TBG is an active carrier and has a possibility to switch between the 
high-affinity and the low-affinity form [78]. TBG levels are the highest in the second and 
third trimester of pregnancy [79,80] and the same holds true for TH-binding ratio [81] and 
thyroid-binding capacity [82], which decreases as soon as 3-4 days after delivery.  
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Abbreviations: T3 is triiodothyronine, T4 is thyroxine, TR is thyroid hormone receptor, RXR is retinoid X receptors, 
TRE is T3-responsive element, nTRE is none T3-responsive element, Ds is deiodonases, S is sulfotransferases, MCT is 
monocarboxylate transporter, OATP is organic anion transporter, MAPK/ERK1/2 is mitogen-activated protein kinase, 
P is phosphorylation and PI-3K is phosphatidylinositol 3-kinase. 
Figure 2. (A) Schematic representation of major thyroid hormone receptors (TRα, β) domains and 
functional sub-regions. (B) General model for genomic and non-genomic actions of TH in both adult 
and fetus; Schematic representation of thyroid hormones (THs; T4 and T3) genomic actions, initiated at 
the nuclear receptors (TRβ), and non-genomic actions, initiated at cytoplasmatic receptors (TRβ, TRα) 
and at the plasma membrane on the membrane receptors, particularly integrin αvβ3 receptor. T4 
binding (but not T3) to cytoplasmic TRα may cause a change of state of actin. T3 binding (but not T4) to 
cytoplasmic TRβ activates the phosphatidylinositol 3-kinase (PI-3K) pathway leading to alteration in 
membrane ion pumps and to transcription of specific genes. TH binding to the integrin receptor results 
in activation of mitogen-activated protein kinase (MAPK/ERK1/2). Phosphorylated MAPK (pMAPK) 
translocates to the nucleus where it phosphorylates transcription factors including thyroid receptors 
(TRβ), estrogen receptor (ER) and signal transducer activators of transcription (STAT). Generally, 
activity is regulated by an exchange of corepressor (CoR) and coactivator (CoA) complexes. 
(A) 
(B) 
 
Thyroid Hormone 134 
TH-binding protein Cellular location 
Transthyretin  Plasma 
T4-binding globulin 
Serum albumin 
Lipoproteins 
Myosin light chain kinase Cytoplasmic 
Pyruvate kinase, subtype M1 
Pyruvate kinase, subtype M2 
Prolyl 4-hydroxylase, b-subunit 
Aldehyde dehydrogenase 
Table 4. Types of thyroid hormone-binding proteins. 
2.4.1. General genomic action (Table 5 and Figure 2) 
T4 and T3 enter the cell through transporter proteins such as MCT8 and 10 or OATPs. Inside 
the cells, deiodinases (DI, II) convert T4, the major form of thyroid hormone in the blood, to 
the more active form T3. DIII produces rT3 and T2 from T4 and T3, respectively [1,73,83]. T3 
binds to nuclear TRs, TRα and TRβ, that activate transcription by binding, generally as 
heterodimers with the retinoid X receptor (RXR) (Table 5) [87], to thyroid hormone response 
elements (TREs) located in regulatory regions of target genes [84]. Activity is regulated by 
an exchange of corepressor (CoR) and coactivator (CoA) complexes. Negative TREs (nTRE) 
can mediate ligand-dependent transcriptional repression, although in this case the role of 
coactivators and corepressors is not well defined [73,85]. TRs can also regulate the activity of 
genes that do not contain a TRE through “cross-talk” with other transcription factors (TF) 
that stimulate target gene expression [28,86]. Both receptors and coregulators are targets for 
phosphorylation (P) by signal transduction pathways stimulated by hormones and growth 
factors [84,85]. Thus, the nuclear actions of T3 are sensitive to inhibitors of transcription and 
translation and have a latency of hours to days [9,73]. Thus, the genomic action will play a 
critical role in the cellular proliferations and differentiations.  
2.4.2. General non-genomic action (Table 5 and Figure 2) 
Although T3 is known to exert many of its actions through the classical genomic regulation 
of gene transcription, a number of T3 effects occur rapidly and are unaffected by inhibitors 
of transcription and protein synthesis [88,89]. However, the levels of circulating THs are 
tightly regulated and stable and thus rapidly mediated responses must involve regulation of 
pre-receptor ligand metabolism, ligand membrane transport or receptor availability leading 
to local cell type specific variation in thyroid hormone signaling [87]. Non-genomic actions 
of THs have been described at the plasma membrane, in the cytoplasm and in cellular 
organelles [15,21,83,90,91]. They have included the modulation of Na+, K+, Ca2+ and glucose 
transport, activation of protein kinase C (PKC), protein kinase A (PKA) and mitogen-
activated protein kinase (ERK/MAPK) and regulation of phospholipid metabolism by 
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activation of phospholipase C (PLC) and D (PLD) [92-94]. Generally, binding of T3 to a 
subpopulation of receptors located outside the nuclei can also cause rapid “non-genomic” 
effects through interaction with adaptor proteins, leading to stimulation of signaling 
pathways. T4 can also bind to putative membrane receptors such as integrin receptor (αVβ3) 
inducing MAPK activity [18,73,95,96]. Thus, several observations suggest that the rapid 
nongenomic effects of TH are widespread and may be involved in multiple physiological 
processes in many different cell types [87]. However, no specific membrane associated TR 
isoform or thyroid hormone binding G protein-coupled receptors (GPCR) have been 
identified or cloned and thus the area remains controversial. 
 
Compare face Ligand Receptor Dimerization
partners
Associated factors or
signalling pathways
Actions 
 
Classical, genomic actions (hours to days)
Nuclear 
transcription 
T3 TRα and
TRβ 
RXR and  
TRs 
 
- NCoR/SMRT Basal - Transcriptional 
repression 
- SRC/p160/TRAPs - Transcriptional 
activation and 
repression 
Non-classical non-genomic actions (seconds to minutes)
Cell surface 
receptor 
T4/T3 Putative
GPCR 
Raf1/MEK/MAPK
 
TR phosphorylation 
and altered 
transcriptional 
activity p53 
phosphorylation and 
general transcriptional 
activity
MEK/STATs Increased STAT 
mediated 
transcription 
Mitochondrial 
gene 
transcription 
T3 TRαp43 mtRXR and 
mtPPAR 
Co-factors? Increased 
mitochondrial gene 
expression 
Mitochondrial 
oxidation 
T3 TRαp28 ANT, UCPs Increased 
thermogenesis 
T2 Cytochrome
-c Va
Increased oxidative 
phosphorylation 
Abbreviations: T4 is Thyroxine, T3 is triiodothyronine, T2 is diiodothyronine, RXR is retinoid X receptor, TR is thyroid 
hormone receptor, GPCR is G protein coupled receptor, mtRXR is mitochondrial retinoid X receptor α isoform, 
mtPPAR is mitochondrial peroxisome proliferator activator receptor γ2 isoform, NCoR is nuclear receptor co-
repressor, SMRT is silencing mediator of RAR and TR, SRC is steroid receptor cooactivator, TRAPs is thyroid receptor 
associated protein, Raf1 is Raf serine/threonine kinase, MEK is mitogen activated protein kinase kinase, MAPK is 
mitogen activated protein kinase, STAT is signal transducers and activators of transcription, ANT is adenine 
nucleotide translocase and UCP is uncoupling protein. 
Table 5. General thyroid hormone actions. 
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There also are reports of nongenomic effects on cell structure proteins by THs. Actin 
depolymerization blocks DII inactivation by T4 in cAMP-stimulated glial cells, suggesting that 
an intact actin cytoskeleton is important for this downregulation of deiodinase activity [9,97]. 
Interestingly, T4, but not T3, can promote actin polymerization in astrocytes [98] and thus may 
influence the downregulation of DII activity by a secondary mechanism, perhaps by targeting 
to lysosomes [9,99]. Moreover, the regulation of actin polymerization and F-actin contents also 
could contribute to the effects of TH on arborization, axonal transport, and cell-cell contacts 
during brain development, where the regulation of these factors is fundamental for the 
organization of guidance molecules such as laminin on the astrocyte plasma membrane and 
modulates integrin–laminin interactions [3]. T4 was required for integrin clustering and 
attachment to laminin by integrin in astrocytes [100]. These data suggest that the non-genomic 
action may play an important role in promoting the normal development. 
3. Maternal-fetal thyroid in normal state 
THs are essential for normal neonatal development in both humans and rodents [3,23,101-104] 
and the experimental work indicated that THs are transported from the mother to the fetus, 
albeit in limited amounts, and that the fetal brain is exposed to THs before initiation of fetal 
TH synthesis [1]. In addition, the maternal TH regulates early fetal brain development in 
human and animal models [2]. The TH of maternal origin can cross the placenta and reach the 
fetus [2,105,106] and that TRs are expressed in the fetal rat brain before the onset of fetal 
thyroid function [107]. Thus, the THs are essential for brain maturation from early embryonic 
stages onward [103,104,108]. However, TH-dependent stages of fetal brain development 
remain to be characterized. Notably, the maternal thyroid is the only source of T4 and T3 for 
the brain of the fetus because its thyroid gland does not start contributing to fetal requirements 
until midgestation in man, and days 17.5–18 in rats [109]. Therefore, the amount of maternal 
T4 that the fetus receives early in pregnancy will determine TH action in its brain because it 
depends on maternal T4 for its intracellular supply of the active form of the hormone, T3. 
However, fetal brain total T3 levels are low (ca. 100 pM) at this time [1], but receptor 
occupancy approximates 25% since free T3 concentrations are high in the nucleus relative to 
the cytosol [110]. In general, materno-fetal transfer of THs has been demonstrated in early fetal 
stages [111] and continues, at least in the case of fetal inability, to produce sufficient TH until 
term [44]. Actually, brain cells can protect themselves against higher fetal T4 and T3 values by 
decreasing DII and increasing DIII activity [2]. Taken together, thyroid activity undergoes 
many changes during normal pregnancy including [1,112-115]: (a) a significant increase in 
serum thyroxine-binding globulin, thyroglobulin, total T4, and total T3; (b) an increase in renal 
iodide clearance; and (c) stimulation of the thyroid by human chorionic gonadotropin (hCG). 
These changes can make diagnosis of thyroid dysfunction during pregnancy difficult.  
4. Maternal-fetal thyroid in hypothyroid state 
THs are important for growth and differentiation of a variety of organs, including the brain. 
In developing brain, THs stimulate and coordinate processes such as neuronal proliferation, 
migration, growth of axons and dendrites, synapse formation and myelination [1,2]. 
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Disturbance of these processes leads to abnormalities in the neuronal network and may 
result in mental retardation and other neurological defects, including impaired motor skills 
and visual processing [115]. If TH deficiency occurs at the perinatal stage, such as in 
congenital hypothyroidism, timely treatment may rescue most of the symptoms. A shortage 
of THs starting at the early stages of pregnancy, such as in cretinism, results in neurological 
deficits that cannot be rescued by exogenous TH addition at later stages [25]. 
The role of THs in brain development has been studied most extensively in the cerebellum 
[23,116]. The cellular proliferation and migration processes are disturbed by TH deficiency 
as investigated predominantly in rodents, where most of cerebellar maturation occurs in the 
early postnatal period [2]. In the hypothyroid cerebellum, the number and length of 
Purkinje cell dendrites is severely reduced [1]. At the same time the granule cell parallel 
fiber growth is reduced, leading to a reduction in axodendritic connections between the 
Purkinje cells and the granule neurons [117]. Additionally, other cell types such as 
astrocytes, Golgi epithelial cells, basket cells, and oligodendrocytes show abnormalities 
under hypothyroid conditions [116]. Several TH target genes have been identified over the 
years, including genes coding for myelin proteins, cytoskeletal proteins, neurotrophins and 
their receptors, transcription factors, and intracellular signaling proteins [118] and recent 
transcriptome analyses continue to increase their number [119-121]. Some of these genes 
only respond to thyroid status for a short and specific period during development, a feature 
that is typical for many TH target genes in brain [122]. Interestingly, a reduction or absence 
of TH during brain maturation yields molecular, morphological and functional alterations in 
the cerebral cortex, hippocampus and cerebellum [123-132]. 
5. Maternal-fetal thyroid in hyperthyroid state (Figure 3) 
Neonatal hyperthyroidism was described as a critical disease marked mainly by cardiac 
symptoms, poor weight gain and severe neurological manifestations [1,133-137]. Fetal 
thyrotoxicosis is the result of thyroid-stimulating antibody transfer to the fetus in the setting 
of maternal Grave’s disease [2,138]. It may present with a variety of clinical features, which 
include persistent sinus tachycardia, fetal hydrops, intrauterine growth restriction, goiter 
and fetal demise [1,139]. The vast majority of cases of excessive serum TH concentration 
seen in pregnancy are due to the overproduction of THs (Graves’ disease, toxic nodular 
goiter); in the postpartum period, thyrotoxicosis may be due to exacerbation of Graves’ 
hyperthyroidism or to the release of thyroid hormone due to an acute autoimmune injury to 
the thyroid tissue (postpartum thyroiditis-PPT) [2,140].  
The management of hyperthyroidism in pregnancy, which most often is caused by Graves’ 
disease, has been reviewed recently [141,142]. Hyperthyroidism occurs in about 0.2–0.4% of all 
pregnancies. Hyperthyroidism should be distinguished from gestational transient 
thyrotoxicosis, which is due to the TSH-receptor stimulating effects of hCG [143,144]. This hCG-
induced hyperthyroidism is mostly mild and need not be treated. Only rare cases with 
extremely high hCG (i.e. due to a hydatidiform mole) might induce severe thyrotoxicosis [145]. 
The signs and symptoms of hyperthyroidism due to Graves’ disease may aggravate in the first 
trimester and thereafter may become mild. Untreated hyperthyroidism is associated with severe 
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effects on maternal and neonatal outcome. The risk for premature fetal loss, preeclampsia, 
preterm delivery, intrauterine growth retardation and low birth weight is significantly 
increased [144]. It has to be considered that the transfer of stimulating receptor antibodies 
(TSAbs) are transferred from the mother to the child, and therefore the fetus is at risk to develop 
Graves’ disease. Close monitoring of the fetus is, therefore, strictly recommended, even in 
mothers treated by thyroidectomy before pregnancy but have still elevated TSAbs [142]. 
 
Figure 3. Different cases of hyperthyroidism. 
Taken together, there are two known causes of central hyperthyroidism [1,146]; (1) TSH-
producing pituitary tumors (TSHomas) and (2) the syndrome of pituitary resistance to 
thyroid hormone (PRTH). In general, thyrotoxicosis is the syndrome resulting from an 
excess of circulating free T4 and/or free T3 [147,148]. Babies likely to become hyperthyroid 
have the highest TSH receptor antibody titer whereas if TSH receptor antibodies are not 
detectable, the baby is most unlikely to become hyperthyroid (Figure 3) [1,2,149]. In the 
latter case, it can be anticipated that the baby will be euthyroid, have transient 
hypothalamic-pituitary suppression or have a transiently elevated TSH, depending on the 
relative contribution of maternal hyperthyroidism versus the effects of maternal antithyroid 
medication, respectively [150].  
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6. Summary  
about the developmental thyroid hormone mechanisms (deiodinases, transporters, 
sulfotransferases and receptors) in human [1,2,50,52,127,130,151-154], rat [1,2,41,60,135,154-
156] and chicken [7,157-170]. Note that the chicken is born early compared to the rat and 
human, as well as the rat is born early compared to the human (Table 6). 
Human Rodent (rat) Chicken 
Week post conception Day post conception Incubation day 
1 W - DIII is detected
in uterine wall. 
1 GD DII and DIII are 
observed in 
uterine wall. 
5 h  
(blastula 
stage) 
- TRα mRNA is noticed and 
the levels markedly increased 
during neurulation. 
3 W - Thyroid gland
begins. 
7 -8.5
GD 
- Time of 
implantation 
process.  
- Very high DIII 
activity is 
detected in 
decidual tissue. 
24 h 
 
- mRNA levels of DI, DII and 
DIII are detected in whole 
embryos. 
4-6 W  - TBG is observed 
in thyroid follicle 
cells at GD 29. 
- TRH is detected 
in fetal whole-
brain at 4.5 weeks 
of gestation. 
- T4 is transferred 
via the placenta 
and has been 
found in the 
gestational fluid 
sac from 4 to 6 W. 
9 GD - Thyroid gland 
is first visible as 
an endodermal 
thickening in the 
primitive buccal 
cavity. 
- TH is detected 
in rat 
embryotrophobl
asts 
48 h - OATP1c1 expression 
appears. 
 
5-11 
W 
- Maternal-embryo 
transfer of THs has 
been detected in 
embryonic 
coelomic fluid and 
amniotic fluid. 
- All the mRNAs 
encoding THTs 
are expressed in 
placenta from 6 W 
and throughout 
pregnancy.
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8 W - T4, T3 and rT3 
are detected in 
coelomic/amniotic 
fluids. 
- TRs, DII and DIII 
are noticed in  
fetal brain. 
10 GD - T4, T3 and TRβ 
are detected in 
embryo/trophobl
ast unit. 
E2-E4 - T3, THTs, Ds and TRs are 
expressed in whole embryos. 
10 W - TSH is first 
detected in the 
fetal pituitary. 
E4 - OATP1c1 expression is 
more than 10-fold higher in 
the telencephalon and 
diencephalon compared to 
the mesencephalon and 
rhombencephalon.  
- DII mRNA levels are 
highest in the diencephalon. 
8-10 
W 
- The fetus is able 
to produce THs 
during this 
period, but prior 
to that time, is 
totally dependent 
on maternal THs. 
E5 - TRα mRNA is widely 
distributed in fore-, mid- and 
hind-brain. 
11 W - TBG levels are 
detected in fetal 
serum and 
increased through 
gestation. 
E6 - T4 and T3 are detected in 
embryonic brain. 
8-11 
W 
- TRH is detected 
in fetal 
hypothalamus. 
E7 - DII activity is observed in 
the brain before the onset of 
thyroid function and 
increases significantly. 
12 W - T4 and T3 are 
observed in serum 
and brain. 
- Total serum T4 
and T3 are low, 
free T4 is 
relatively high.  
- rT3 is noticed in 
serum relatively 
high. 
- TH synthesis 
begins in fetal 
thyroid. 
13 GD - Placental 
circulation 
established. 
- TRs and TH are 
observed in fetal 
brain. 
- DIII and DII are 
detected in 
uterus and 
placenta. 
E8 - DII mRNA is noticed in cell 
clusters throughout the 
brain, particularly in 
rhombencephalon.  
- OATP1c1 levels are 
declined substantially in all 
brain regions. 
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- Decreased 
mRNA expression 
of OATP1A2 but 
no change for 
OATP4A1 at 9–12 
W compared to 
term. 
14 W - Expressions of 
mRNAs encoding 
MCT8, MCT10, 
OATP1A2 and 
LAT1 are 
significantly 
lower prior to 14 
W compared to 
term 
 
14 GD - TRH mRNA is 
detected in 
neurons of the 
fetal 
hypothalamus. 
E4-E8 - DIII mRNA levels are 
markedly different in the 
telencephalon and 
diencephalon but remain 
stable, while the levels in 
mesencephalon and 
rhombencephalon show a 
sharp decrease and increase, 
respectively, during these 
days. 
15 GD - Pituitary TSH 
mRNA 
expression 
begins. 
- TRH mRNA is 
detected in the 
developing 
paraventricular 
nuclei of the 
hypothalamus. 
E9-10 - Several elements of the TH 
action cascade are present in 
the brain of embryos long 
before their own thyroid 
gland starts hormone 
secretion. 
16 W - DIII is observed 
in placenta and 
fetal epithelial 
cells. 
- DIII and TRs are 
detected in fetal 
liver. 
- DI is noticed in 
heart and lung. 
- Significant fetal 
TH secretion 
begins. 
16-19.5 
GD 
- TRs are 
observed in liver, 
heart and lung. 
- DI and DII are 
noticed in fetal 
tissues. 
- TRH is 
produced in low 
levels in 
hypothalamus 
and increases 
approximately 
threefold by 
GDI9.5. 
E10  - The thyroid gland is fully 
functional. 
16-20 
W 
- Duplication of 
TBG 
concentrations. 
17 GD - TH synthesis 
begins in fetal 
thyroid  
E13 - Brain DII is elevated at the 
peak of neuroblast 
proliferation. 
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- TSH protein and 
Sulfotransferase 
are observed. 
 
18 -22 
GD 
- The total T4 and 
T3 concentrations 
in fetuses are 
increased drama-
tically because of 
maturation of 
hormone 
synthesis of the 
fetal thyroid 
gland. 
- The 
coordination 
between THTs 
and Ds is 
regulated both 
transplacental 
TH passage from 
mother to fetus 
and the 
development of 
the placenta itself 
through the 
progress of 
gestation. 
E14 - The strong increase in 
intracellular T3 has been 
observed. 
20 W - A steady 
increase in serum 
TH levels begins 
and continues to 
term. 
19 GD - Significant fetal 
TH secretion 
begins. 
- Marked rise in 
serum TH but 
levels at birth 
still below those 
in adult. 
E15 - Plasma T4 levels start rising 
markedly around this day. 
22-32 
W 
- Serum total and 
free T4 and T3 
near and below 
adult levels, 
respectively. 
- The HPT axis 
begins to mature 
during the second 
half of gestation. 
22 GD  - Birth state. 
- Thyroid system 
is less 
developed.  
- As much as 
17.5% of THs 
found in the 
newborn are of 
maternal origin.  
E16 - The decrease in DI activity 
in gonads is combined with 
the relatively high DIII 
activity. 
- A significant increase in T3 
production and in DII-activity 
and -mRNA expression are 
combined with a decreased in 
DIII activity. 
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- LAT1 and 
OATP4A1 have 
been localized 
only during the 
third trimester. 
40 W  - Birth state. 
- Complete 
maturation of 
thyroid system. 
- MCT8 has been 
localized in the 
placenta in all 
three trimesters of 
pregnancy. 
- High 
concentrations of 
the different 
iodothyronine 
sulfates, T4S, T3S, 
rT3S and T2S, 
have been 
documented in 
human fetal and 
neonatal plasma 
as well as in 
amniotic fluid 
during the 
pregnancy. 
10 PND - Brain 
development 
equivalent to 
human birth. 
E13/14–
E17 
(synapt
ogenesis
) 
- Brain DII activity is 
moderately elevated, 
whereas DIII activity and 
mRNA expression are 
highest between these days, 
followed by a dramatic 
decrease thereafter. 
10-20 
PND 
- Serum TH 
levels continue 
to rise and are 
higher than 
adult levels 
between these 
days. 
E18 - DI and DIII are expressed in 
the granule cells, whereas DII 
is found mostly in the 
molecular layer and the 
Purkinje cells at that time. 
14-50 
PND 
- The levels of 
pituitary and 
serum TSH 
slowly decrease 
from PND 14–16 
until reaching 
adult levels at 
PND 40. 
- TRH levels 
increase to adult 
levels by PNDI7–
29, then decrease 
transiently 
between PND 
31–41; adult 
levels are once 
again reached at 
PND 50. 
- Adult TRH 
mRNA 
expression 
patterns are 
present at PND 
22. 
E19 - The increase in brain T3 
production correlates with 
the appearance of TRβ 
expression in the cerebellum, 
telencephalon and optic 
lobes. 
E20 (at 
the 
moment 
of 
pipping
) 
- The brain is quite well 
developed at the time of 
hatching. 
- The gradual increases in 
plasma T4 and hepatic DI are 
detected. 
- DIII levels are decreased in 
spleen and increased in skin 
and the lungs towards 
hatching. 
- T3 production seems to be 
elevated markedly in liver. 
- The rise of T4 is much more 
pronounced than in plasma. 
- Diminished T4 sulfation is 
detected. 
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30 PND Complete 
maturation of 
thyroid gland. 
E14-
E19/20 
- The T3 breakdown capacity 
by DIII is high in liver but 
low in kidney. 
E15/16-
E20 
- T4 levels in plasma increase 
gradually during these days.  
- In contrast to TRα 
expression which increases 
gradually towards hatching, 
expression of TRβ shows an 
abrupt elevation in late 
development, especially in 
the cerebellum.  
- The majority of tissues 
express DIII together with 
either DI or DII. 
E17-E20 - The levels of DIII activity 
present in liver are rapidly 
drop by more than 90%.  
- DI levels in testis and ovary 
strongly decrease around 
hatching.  
E18–E20 - Brain DII activity is 
moderately decreased, 
whereas DIII activity is low. 
E19-E20 - The low T3/T4 ratio is 
associated with high T3 
breakdown in liver and with 
high T4 inactivation or T3 
secretion in kidney. 
E20-C0 - DI activity gradually 
increases, reaching a 
maximum around these 
period, and decreases slowly 
to posthatch levels thereafter. 
C1 (first 
day 
post-
hatch) 
- The expression of DI is 
limited to the mature granule 
cells and that of DIII to the 
Purkinje cells exclusively, 
whereas DII remains clearly 
present in the molecular 
layer. 
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C2 - Highest DI-activities and -
mRNA expressions are 
detected in the liver, kidney, 
and intestine. 
C1-C7 - The circulating T3/T4 ratio 
started to increase gradually 
during the first week after 
hatching. 
Abbreviations: W is week, GD is gestation day, E is incubation day, PND is postnatal day, C is posthatch day, THs is 
thyroid hormones, TRH is thyroid releasing hormone, TSH is thyroid stimulating hormone, THTs is thyroid hormone 
transporters, MCT is monocarboxylate transporter, OATP is organic anion transporter, Ds is deiodinases (DI, II, III), 
TRs is thyroid hormone receptors (TRα, β), T4 is Thyroxine, T3 is triiodothyronine, rT3 is reverse triiodothyronine, T2S 
is diiodothyronine sulfate, T3S is triiodothyronine sulfate, T4S is thyroxine sulfate, rT3S is reverse triiodothyronine 
sulfate, HPT is hypothalamic-pituitary-thyroid axis and TBG is thyroxin binding globulin. 
Table 6. Summary about the developmental thyroid hormone mechanisms (deiodinases, transporters, 
sulfotransferases and receptors) in human, rat and chicken. 
7. Conclusion 
The actions of THs are highly pleiotropic, affecting many tissues at different developmental 
stages. As a consequence, their effects on proliferation and differentiation are highly 
heterogeneous depending on the cell type, the cellular context, and the developmental or 
transformation status. 
Maternal THs are important in promoting normal fetal development especially the placental 
and CNS development. Clinical epidemiological and basic findings clearly show that 
maintaining normal TH regulation from the beginning of pregnancy is important to reduce 
the risk of obstetric complications and to ensure optimal neurodevelopment of the offspring.  
In normal pregnancy, transplacental TH passage is modulated by plasma membrane THTs, 
Ds, sulfotransferases, TRs and several different proteins within placental cells.  
In pathological/abnormal pregnancies with either maternal or fetal THs disturbances (hypo- 
or hyper-thyroidism), the placenta lacks the full compensatory mechanisms necessary to 
optimize the maternal–fetal transfer of THs to achieve the normality of TH levels in the 
fetus. 
8. Future challenges 
Further studies are still needed to improve our understanding of the mechanisms mediating 
the transplacental transport of THs in both human and animals, particularly the role of the 
different THTs, and the mechanisms that ensure that sufficient amounts of THs are 
protected from D3 inactivation during their transit across the placenta. Such knowledge 
would facilitate the development of interventions to increase TH passage in pathological 
situations, in order to ensure normal fetal development. A better understanding of these 
mechanisms would also permit us to refine the timing and dosage of the increase in 
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levothyroxine therapy in hypothyroid pregnant women and to establish whether thyroxine 
on its own is indeed the best form of TH replacement in pregnancy.  
Elucidation of tissue-, cell-, and sex-specific expression of individual Ds and THTs during 
the development of both human and animals, in the adult, during aging and when sick. 
I hope that new insights into the complex actions by which the THs and their receptors 
control cell proliferation and differentiation will be provided in the near future. 
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